Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Research & Development (2017 - 2025)

Organogenesis Holdings has reported Research & Development over the past 9 years, most recently at $10.3 million for Q4 2025.

  • Quarterly results put Research & Development at $10.3 million for Q4 2025, down 10.79% from a year ago — trailing twelve months through Dec 2025 was $44.5 million (down 11.4% YoY), and the annual figure for FY2025 was $44.5 million, down 11.4%.
  • Research & Development for Q4 2025 was $10.3 million at Organogenesis Holdings, down from $13.2 million in the prior quarter.
  • Over the last five years, Research & Development for ORGO hit a ceiling of $15.6 million in Q2 2024 and a floor of $6.2 million in Q1 2021.
  • Median Research & Development over the past 5 years was $10.4 million (2023), compared with a mean of $10.5 million.
  • Biggest five-year swings in Research & Development: skyrocketed 141.39% in 2021 and later plummeted 33.31% in 2025.
  • Organogenesis Holdings' Research & Development stood at $8.3 million in 2021, then skyrocketed by 37.95% to $11.4 million in 2022, then grew by 3.29% to $11.8 million in 2023, then dropped by 2.04% to $11.5 million in 2024, then dropped by 10.79% to $10.3 million in 2025.
  • The last three reported values for Research & Development were $10.3 million (Q4 2025), $13.2 million (Q3 2025), and $10.4 million (Q2 2025) per Business Quant data.